Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524500 | NSE Symbol : KILITCH | ISIN : INE729D01010 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
12-Jul-2025	12-Jul-2025	Right Issue	Board meeting to approve issue period and letter of offer Submission of Corrigendum of Outcome of Board meeting held on July 12, 2025
09-Jul-2025	09-Jul-2025	Right Issue	Issue of equity shares of company on right issue basis Board of Directors meeting held today, i.e., July 9, 2025, has, inter alia, considered and approved the following terms of the Rights Issue: Total number of securities proposed to be 13,98,463 fully paid-up Equity Shares of issued 2 (Two) Rights Equity Shares of 210/ - each for every 23 (Twenty-Three) Equity Shares of %10/ - each held by the Eligible Equity Shareholders in the Company as on the record date, with the right to renounce. Issue Price Rs. 357/- per Rights Equity Share (including premium of 347/- per Rights Equity Share and Face Value of 10/ - each). Outstanding Equity Shares prior to the 1,60,82,319 Equity Shares of 10/- each Rights Issue Outstanding Equity Shares post Rights 1,74,80,782 Equity Shares of %10/- each Issue (assuming full subscription) (assuming full subscription).
29-Jun-2025	02-Jul-2025	Raising funds through Debt Instr.	Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2025 inter alia to consider and approve for fund raising by way of issue of equity shares through right issue through right issue Raising of Fund by way of issue of equity shares of the company on right issue basis (As Per BSE Announcement Dated on :02.07.2025)
13-May-2025	19-May-2025	Quarterly Results	Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter ended 31st March 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 19/05/2025)
03-Feb-2025	11-Feb-2025	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve unaudited standalone and consolidated financial results for the quarter ended 31st December 2024 Considered and Approved unaudited financial results for quarter ending 31st December, 2024 (As per BSE Announcement Dated on 11/02/2025)
04-Nov-2024	12-Nov-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th September 2024. We are submitting herewith the financial results for the quarter ended 30th September, 2024 (As Per BSE Announcement Dated on: 12/11/2024)
30-Aug-2024	30-Aug-2024	Change in Auditors	Pursuant to Regulation 30 of SEBI LODR Regulations, this is to inform you that the Board of Directors approved the appointment of M/s C Sharat & Company, Chartered Accountants as a Statutory Auditors of the Company
26-Aug-2024	26-Aug-2024	Change in Auditors	Appointment of M/s. AVHP & Company LLP, Chartered Accountant (FRN:W100671) as Statutory Auditors of the Company
01-Aug-2024	08-Aug-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve unaudited financial results for the period ended 30th June 2024 Submission of Quarterly Standalone and Financial Results for the quarter ended 30th June 2024 (As Per BSE Announcement Dated on: 08/08/2024)
20-May-2024	27-May-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2024 inter alia to consider and approve financial results for the quarter and year ended 31st March 2024 Financial Results for the year ended 31st March, 2024 Quarterly financial results for the year ended 31st March, 2024 (As Per BSE Announcement Dated on 27.05.2024)
31-Jan-2024	08-Feb-2024	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/02/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 31st December 2023 Declaration of Financial Results for the quarter ended 31st December, 2023 Submission of financial results for the quarter ended 31st December, 2023 (As Per BSE Announcement dated on 08.02.2024)
01-Nov-2023	09-Nov-2023	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2023 inter alia to consider and approve and consider the unaudited Financial Results (Standalone and Consolidated) of the Company for the half year ended 30th September 2023. Enclosed please find Financial Results for the quarter ended 30th September, 2023 (As Per BSE Announcement dated on 09.11.2023)
04-Aug-2023	11-Aug-2023	Quarterly Results	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2023 inter alia to consider and approve Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that the meeting of the Board of Directors of the Company will be held on Friday 11th August 2023 inter-alia to consider and approve the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June 2023. Considered and approved financial results for the quarter ended 30th June, 2023 Details of the agenda approved at the meeting is enclosed herewith (As Per BSE Announcement Dated on 11.08.2023)
29-Jul-2023	29-Jul-2023	Others	Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday, 29th July, 2023 considered and approved obtaining credit facilities from bank, in aggregate, not exceeding Rs. 100 crore for the purpose of meeting fund requirements of the company.
19-Jul-2023	22-Jul-2023	Conversion	KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2023 inter alia to consider and approve To consider and approve conversion of warrants into the equity shares of the Company to the specified person only Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday, 22nd July, 2023 considered and approved the following; Obtaining credit facilities from bank not exceeding Rs. 50,50,00,000 for the purpose of meeting day to day fund requirements of the Company. Conversion of 5,00,000 convertible warrants into 5,00,000 equity shares of face value of Rs. 10/- each of the Company out of the warrants allotted on 24th January, 2023 on preferential allotment basis to the allottees pursuant to exercise of their rights of conversion of warrants into equity shares and accordingly the Board of Directors have allotted 5,00,000 equity shares of face value of Rs. 10 each fully paid up on account of conversion (As Per BSE Announcement Dated on 22/07/2023)

1 2 3

LOGIN HERE

Kilitch Drugs (India) Ltd

Board Meeting